Governance Revolution Medicines, Inc.

Equities

RVMD

US76155X1000

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2025-02-07 pm EST 5-day change 1st Jan Change
42.19 USD -3.17% Intraday chart for Revolution Medicines, Inc. -1.77% -3.54%

Executive Committee: Revolution Medicines, Inc.

Manager
Positions heldSince
Mark Goldsmith

Mark Goldsmith

63 year

Chief Executive Officer 2014-10-31
Founder 2014-09-30
President 2014-10-31
Luan M. Wilfong

Luan M. Wilfong

Human Resources Officer 2015-03-04
Wei Lin

Wei Lin

64 year

Chief Tech/Sci/R&D Officer 2023-03-31
Jeff Cislini

Jeff Cislini

50 year

General Counsel 2022-08-31
Corporate Secretary 2022-08-31
Wally Reiher

Wally Reiher

Chief Tech/Sci/R&D Officer 2020-08-31
Jack Anders

Jack Anders

48 year

Director of Finance/CFO 2018-09-30
Steve Kelsey

Steve Kelsey

64 year

Chief Tech/Sci/R&D Officer 2017-02-28
Peg Horn

Peg Horn

62 year

Chief Operating Officer 2018-09-30

Composition of the Board of Directors: Revolution Medicines, Inc.

Director
CommitteesSince
Mark Goldsmith

Mark Goldsmith

63 year

Chairman
Elizabeth Anderson

Elizabeth Anderson

67 year

Compensation Committee Chair
Governance Committee Chair
Nominating Committee Chair
Governance Committee 2019-07-09
Nominating Committee 2019-07-09
Audit Committee 2022-08-31
Compensation Committee 2022-08-31
Lorence Kim

Lorence Kim

50 year

Audit Committee Chair 2023-09-04
Governance Committee Chair
Nominating Committee Chair
Executive Committee 2022-09-30
Compensation Committee
Finance Committee Chair 2022-09-30
Audit Committee 2023-09-30
Barbara Weber

Barbara Weber

68 year

Governance Committee
Nominating Committee
Audit Committee 2021-09-30
Compensation Committee 2021-09-30
Governance Committee Chair 2021-09-30
Nominating Committee Chair 2021-09-30
Alexis Borisy

Alexis Borisy

53 year

Compensation Committee 2015-05-03
Governance Committee
Nominating Committee
Audit Committee
Sandra Horning

Sandra Horning

76 year

Governance Committee 2020-02-29
Nominating Committee 2020-02-29
Thilo Schroeder

Thilo Schroeder

43 year

Audit Committee 2018-02-28
Flavia Borellini

Flavia Borellini

66 year

Compensation Committee
Sushil Patel

Sushil Patel

53 year

Audit Committee 2022-06-15
Franklin Clyburn

Franklin Clyburn

60 year

Director/Board Member 2024-08-04
Independent Dir/Board Member 2024-08-04

Former Officers and Directors: Revolution Medicines, Inc.

Insider
Positions held
SinceUntil
Daniel Simon
Daniel Simon
Corporate Officer/Principal 2022-08-31 2023-12-31
Eric Schmidt
Eric Schmidt
Director/Board Member 2020-06-16 2023-09-04
Independent Dir/Board Member 2020-06-16 2023-09-04
Neil Exter
Neil Exter
Director/Board Member 2019-06-30 2022-07-11
Independent Dir/Board Member 2019-06-30 2022-07-11
Vincent A. Miller
Vincent A. Miller
Director/Board Member 2017-08-31 2022-06-15
Independent Dir/Board Member 2017-08-31 2022-06-15
Peter Svennilson
Peter Svennilson
Director/Board Member 2020-06-16 2021-06-21
Independent Dir/Board Member 2020-06-16 2021-06-21
Larry Lasky
Larry Lasky
Director/Board Member 2016-12-19 2020-06-16
Independent Dir/Board Member 2016-12-19 2020-06-16
Ryan Martins
Ryan Martins
Director of Finance/CFO 2018-02-28 2018-09-30
Michael Bonney
Michael Bonney
Director/Board Member 2016-07-31 2017-08-31
Abraham Bassan
Abraham Bassan
Corporate Officer/Principal 2014-11-30 2017-06-30
Martin D Burke
Martin D Burke
Founder 2014-09-30 2016-12-17
Michael Fischbach
Michael Fischbach
Founder 2014-09-30 2016-12-17
Kevan Shokat
Kevan Shokat
Founder 2014-09-30 2016-12-17
Georgia Erbez
Georgia Erbez
Director of Finance/CFO 2016-04-30 2016-08-31
David Pompliano
David Pompliano
Chief Tech/Sci/R&D Officer 2014-09-30 -
Founder 2014-09-30 -
Carole A. Sable
Carole A. Sable
Chief Tech/Sci/R&D Officer 2015-03-04 -
Elaine Heron
Elaine Heron
Director/Board Member - -

Age distribution of managers

Parity Men Women

Male 16
Female 3

Of which Executive Committee

Male 7
Female 1

Of which Directors

Male 9
Female 1

Revisions

1 year Revenue revision
-
4 months Revenue revision
-
1 months Revenue revision
-
1 year EPS revision
-
4 months EPS revision
-
ESG MSCI
B

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
-
ESG: Human rights controversies
-
ESG: Tax subsidies controversies
-
Sharia compliant
-
Logo Revolution Medicines, Inc.
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.
Employees
490
More about the company